From a respected poster on IHUB, Fletch falcon
Post# of 1460
(Total Views: 634)
Posted On: 01/04/2018 11:30:23 AM
From a respected poster on IHUB,
Fletch
falconer66a Thursday, 01/04/18 11:19:19 AM
Re: powerwalker post# 136252
Post # of 136295
Yes, Anavex 3-71 Alone
Thank you, I did not make that clear. This study surely involved only one variable, the presence of Anavex 3-71, alone. That was not specifically stated in any elaborated degree in the abstract, but clearly this was the case. The study was not conducted to discern or discover any combined efficacies; merely, does the stuff, alone, treat Alzheimer’s. And, in these transgenic Alzheimer’s rats, it so clearly did.
And yes (my error), the treatment period was 5 months, not the “5 weeks” I mistakenly stated. Good enough.
Anavex 3-71 works for Alzheimer’s as well as Anavex 2-73. Even better, the intracellular fix persists after dosing stops.
(And, that may, most likely, be eventually shown for Anavex 2-73, too.)
And here is the importance of that. (No one has posted this — really important.)
The fact that efficacy persists after a useful, symptom-treating dosing period is terminated, means, most likely, that the drug continues to be effective throughout treatment periods. Extremely important. Many, perhaps most neurologic drugs lose efficacy over time. They become less effective. Dosages need to be increased, while results continue to degrade. Finally, the drug no longer works for the disease it is being treated for.
Such is the case, of course, for all of the other four FDA-approved Alzheimer’s treatment drugs. They do work, for a while. They keep symptoms from progressing, holding symptom severities at start-of-treatment baselines. Then, severities return and Alzheimer’s resumes its lethal course.
The new murine Anavex 3-72 study rather strongly indicates that none of that will occur.
No loss of potency with the Anavex sigma-1 receptor agonists against, at least, Alzheimer’s — probably the others, too, inasmuch as the mechanism of action (restoration of mitochondrial function) is the same.
Because those without understandings of cellular chemistry so conveniently lump the Anavex drugs and treatment approach in with the always-fails waste protein treatments, they will likewise presume that the Anavex drugs will show to be effective only for a period. They are nerve and brain treatment drugs, and naive investors “know” that almost all of these drugs simply lose efficacy, strength during treatment. They only work for a while. Such will be the case with the Anavex molecules, they are certain.
Ha.
Fletch
falconer66a Thursday, 01/04/18 11:19:19 AM
Re: powerwalker post# 136252
Post # of 136295
Yes, Anavex 3-71 Alone
Thank you, I did not make that clear. This study surely involved only one variable, the presence of Anavex 3-71, alone. That was not specifically stated in any elaborated degree in the abstract, but clearly this was the case. The study was not conducted to discern or discover any combined efficacies; merely, does the stuff, alone, treat Alzheimer’s. And, in these transgenic Alzheimer’s rats, it so clearly did.
And yes (my error), the treatment period was 5 months, not the “5 weeks” I mistakenly stated. Good enough.
Anavex 3-71 works for Alzheimer’s as well as Anavex 2-73. Even better, the intracellular fix persists after dosing stops.
(And, that may, most likely, be eventually shown for Anavex 2-73, too.)
And here is the importance of that. (No one has posted this — really important.)
The fact that efficacy persists after a useful, symptom-treating dosing period is terminated, means, most likely, that the drug continues to be effective throughout treatment periods. Extremely important. Many, perhaps most neurologic drugs lose efficacy over time. They become less effective. Dosages need to be increased, while results continue to degrade. Finally, the drug no longer works for the disease it is being treated for.
Such is the case, of course, for all of the other four FDA-approved Alzheimer’s treatment drugs. They do work, for a while. They keep symptoms from progressing, holding symptom severities at start-of-treatment baselines. Then, severities return and Alzheimer’s resumes its lethal course.
The new murine Anavex 3-72 study rather strongly indicates that none of that will occur.
No loss of potency with the Anavex sigma-1 receptor agonists against, at least, Alzheimer’s — probably the others, too, inasmuch as the mechanism of action (restoration of mitochondrial function) is the same.
Because those without understandings of cellular chemistry so conveniently lump the Anavex drugs and treatment approach in with the always-fails waste protein treatments, they will likewise presume that the Anavex drugs will show to be effective only for a period. They are nerve and brain treatment drugs, and naive investors “know” that almost all of these drugs simply lose efficacy, strength during treatment. They only work for a while. Such will be the case with the Anavex molecules, they are certain.
Ha.
(1)
(0)